1370 related articles for article (PubMed ID: 19835828)
1. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
[TBL] [Abstract][Full Text] [Related]
2. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.
Langley JM; Frenette L; Ferguson L; Riff D; Sheldon E; Risi G; Johnson C; Li P; Kenney R; Innis B; Fries L
J Infect Dis; 2010 Jun; 201(11):1644-53. PubMed ID: 20423222
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.
Díez-Domingo J; Garcés-Sanchez M; Baldó JM; Planelles MV; Ubeda I; JuBert A; Marés J; Moris P; Garcia-Corbeira P; Dramé M; Gillard P
Pediatr Infect Dis J; 2010 Jun; 29(6):e35-46. PubMed ID: 20375709
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
Roman F; Vaman T; Gerlach B; Markendorf A; Gillard P; Devaster JM
Vaccine; 2010 Feb; 28(7):1740-5. PubMed ID: 20034605
[TBL] [Abstract][Full Text] [Related]
5. Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: results of a randomised single heterologous booster dose study at 15 months.
Risi G; Frenette L; Langley JM; Li P; Riff D; Sheldon E; Vaughn DW; Fries L
Vaccine; 2011 Aug; 29(37):6408-18. PubMed ID: 21554915
[TBL] [Abstract][Full Text] [Related]
6. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF
Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults.
Chu DW; Hwang SJ; Lim FS; Oh HM; Thongcharoen P; Yang PC; Bock HL; Dramé M; Gillard P; Hutagalung Y; Tang H; Teoh YL; Ballou RW;
Vaccine; 2009 Dec; 27(52):7428-35. PubMed ID: 19683087
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
Nolan T; Richmond PC; Formica NT; Höschler K; Skeljo MV; Stoney T; McVernon J; Hartel G; Sawlwin DC; Bennet J; Ryan D; Basser RL; Zambon MC
Vaccine; 2008 Nov; 26(50):6383-91. PubMed ID: 18801398
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch.
Glenn GM; Thomas DN; Poffenberger KL; Flyer DC; Ellingsworth LR; Andersen BH; Frech SA
Vaccine; 2009 Dec; 27 Suppl 6():G60-6. PubMed ID: 20006142
[TBL] [Abstract][Full Text] [Related]
11. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults.
Schwarz TF; Horacek T; Knuf M; Damman HG; Roman F; Dramé M; Gillard P; Jilg W
Vaccine; 2009 Oct; 27(45):6284-90. PubMed ID: 19856521
[TBL] [Abstract][Full Text] [Related]
12. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
Levie K; Leroux-Roels I; Hoppenbrouwers K; Kervyn AD; Vandermeulen C; Forgus S; Leroux-Roels G; Pichon S; Kusters I
J Infect Dis; 2008 Sep; 198(5):642-9. PubMed ID: 18576945
[TBL] [Abstract][Full Text] [Related]
13. Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming.
van der Velden MV; Aichinger G; Pöllabauer EM; Löw-Baselli A; Fritsch S; Benamara K; Kistner O; Müller M; Zeitlinger M; Kollaritsch H; Vesikari T; Ehrlich HJ; Barrett PN
Vaccine; 2012 Sep; 30(43):6127-35. PubMed ID: 22884662
[TBL] [Abstract][Full Text] [Related]
14. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age.
Roman F; Vaman T; Kafeja F; Hanon E; Van Damme P
Clin Infect Dis; 2010 Sep; 51(6):668-77. PubMed ID: 20687838
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine.
Tambyah PA; Wilder-Smith A; Pavlova BG; Barrett PN; Oh HM; Hui DS; Yuen KY; Fritsch S; Aichinger G; Loew-Baselli A; van der Velden M; Maritsch F; Kistner O; Ehrlich HJ
Vaccine; 2012 Jan; 30(2):329-35. PubMed ID: 22080174
[TBL] [Abstract][Full Text] [Related]
16. Cross-clade immunogenicity and antigen-sparing with an AS03(A)-adjuvanted prepandemic influenza vaccine in a Thai population.
Thongcharoen P; Auewarakul P; Hutagalung Y; Ong G; Gillard P; Drame M; Bock HL
J Med Assoc Thai; 2011 Aug; 94(8):916-26. PubMed ID: 21863672
[TBL] [Abstract][Full Text] [Related]
17. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: a randomized controlled clinical trial.
Langley JM; Frenette L; Jeanfreau R; Halperin SA; Kyle M; Chu L; McNeil S; Dramé M; Moris P; Fries L; Vaughn DW
Vaccine; 2015 Jan; 33(4):559-67. PubMed ID: 25448092
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits.
Heldens JG; Glansbeek HL; Hilgers LA; Haenen B; Stittelaar KJ; Osterhaus AD; van den Bosch JF
Vaccine; 2010 Nov; 28(51):8125-31. PubMed ID: 20950729
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial.
Wu J; Liu SZ; Dong SS; Dong XP; Zhang WL; Lu M; Li CG; Zhou JC; Fang HH; Liu Y; Liu LY; Qiu YZ; Gao Q; Zhang XM; Chen JT; Zhong X; Yin WD; Feng ZJ
Vaccine; 2010 Aug; 28(38):6221-7. PubMed ID: 20638454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
